Cargando…
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
Prophylaxis with regular infusions of factor VIII (FVIII)- or factor IX (FIX)- containing products is the mainstay of modern hemophilia care. However, this therapeutic regimen is inconvenient, requiring repeated intravenous injections from childhood. Approaches meant to prolong the half-life of FVII...
Autores principales: | Mancuso, Maria Elisa, Mannucci, Pier Mannuccio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974692/ https://www.ncbi.nlm.nih.gov/pubmed/24729686 http://dx.doi.org/10.2147/DDDT.S47312 |
Ejemplares similares
-
Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023) -
The management of hemophilia in elderly patients
por: Franchini, Massimo, et al.
Publicado: (2007) -
Hemophilia therapy: the future has begun
por: Mannucci, Pier Mannuccio
Publicado: (2020) -
Aging with Hemophilia: The Challenge of Appropriate Drug Prescription
por: Mannucci, Pier Mannuccio
Publicado: (2019) -
How we manage cardiovascular disease in patients with hemophilia
por: Franchini, Massimo, et al.
Publicado: (2023)